A study to assess the safety and tolerability of durvalumab as monotherapy and in combination therapy in people with lymphoma or chronic lymphocytic leukemia Dose finding part (Phase 1): - To assess the safety and tolerability of durvalumab when given in combination with lenalidomide and rituximab; ibrutinib; or bendamustine and rituximab to determine the...

• Country None
• organs None
• Specialty None

A study to assess the safety and clinical activity of durvalumab as combination therapy on previously untreated people with high risk diffuse large b-cell lymphoma The primary objective of the study is to explore the clinical activity of durvalumab (MEDI4736) in combination with R-CHOP (non-activated B-cell) or R2-CHOP (activated B-cell) followed by durvalumab c...

• Country None
• organs None
• Specialty None

A study designed to investigate how radiolabelled RPC1063 is taken up, broken down and removed from the body The primary objectives of the study are: •To determine how the drug [14C]-RPC1063 moves through the body and how fast it is removed from the body •To assess the amount of radioactivity found in bloo...

• Country None
• organs None
• Specialty None